Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH35324 in atopic healthy subjects or mild allergic diseases
NCT05061524Phase 1Completed
- Sponsor
- Yuhan
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YH35324 in IgE-mediated allergic diseases (3 arms), sponsored by Yuhan. Primary endpoint: Incidence and severity of adverse events at 113 days. Started Sep 2021; status: completed.
02
Drugs
YH35324
03
Conditions
IgE-mediated allergic diseases
Beyond the preview
Go deeper on NCT05061524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061524.